AiCuris announces strategic shift in focus

Wuppertal, Germany-based infectious disease drug developer AiCuris Anti-infective Cures today announced that it has sharpened its strategic focus on the development of novel, therapeutic candidates for the prevention and treatment of moderate to severe and potentially life-threatening infectious diseases in immunocompromized patients.

AiCuris says this decision enables the company to accelerate its development efforts, prepare for market launch and further build its expertise in an area of medical need that will become increasingly important as the population of immune-compromized patients grows worldwide.

With AiCuris’ enhanced focus on development and commercialization of anti-infectives for immunocompromized individuals, it will discontinue research activities outside of this strategic scope.